Scholars Central

Conference abstractPublished 3 Oct 2016

Updates on systemic AL amyloidosis

Authors: Chakra P Chaulagain

Cleveland Clinic Florida, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Systemic AL amyloidosis (AL) is a multisystem disease characterized by organ damage due to monoclonal free light chains produced in the bone marrow by a neoplastic clone of plasma cells. The clone can be targeted by various treatments with the goal of curbing the production of the organ toxic light chains and thereby stopping and possibly reversing the organ damage present at the time of diagnosis. AL amyloidosis remains an incurable disease despite treatment options that include steroids, cytotoxic chemotherapy, risk-adapted melphalan and autologous hematopoietic stem cell transplantation, proteasome inhibitors and immunomodulatory drugs. Newer and effective treatment approaches that can rapidly reverse the organ damage are urgently needed. Monoclonal antibodies targeting the plasma cells may become available in future for management of this disease. An updates for the practicing clinicians as well as the areas of future research will be reviewed in this presentation.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • BylineArticles whose byline prints “Chakra P Chaulagain”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels